Hims House
Jonathan Stern, Patrick Lester
himshouse1@gmail.com
Booking Overview
Hims House is a weekly, investor-focused look at Hims & Hers—telehealth, compounding/GLP-1 dynamics, and future healthcare bets. It’s especially strong for experts who can speak to pharma/clinical evidence, regulatory pathways, and market structure behind Hims’ growth narrative.
Metrics
65 episodes, Weekly, 5.0 rating
<1k, Male, USA
YouTube: 5.2k subscribers
Contact Information
himshouse1@gmail.com
Description
Hims House is the ultimate podcast for Hims & Hers investors. Hosted by Jonathan Stern and Patrick Lester, Hims House breaks down all the key questions shaping $HIMS — from telehealth and pharma to GLP-1s, compounding, and the future of healthcare. New episodes every week. himshouse.substack.com
Production Team
Host
Jonathan Stern, Patrick Lester
Categories
Investing, Business, Business News, Health & Fitness, Technology
Booking Intelligence
Booking Requirements
medium
Typical Credentials:
Investors, healthcare analysts, founders/executives of relevant companies (telehealth, peptides/compounding, GLP-1 supply chain, longevity), or high-signal public experts with direct exposure to FDA pathways, clinical trials, and Hims/compounding market structure.
Required Achievements:
Notable healthcare investment track record (analyst or fund management), Founder/C-suite leadership in healthcare, longevity, peptides, or GLP-1 ecosystem companies, Significant ownership/investor relationship to Hims & Hers (frequently large shareholders), Visible involvement in clinical trial design/execution or regulatory strategy, Media/public recognition within biotech/health-investing circles
Recent Guest Discussions
Christian Angermayer - Athlete Clinical Study Rationale; Peptides/ped Policy Argumentation; Consumer Health And Longevity Launch Plans; Market/positioning; Apeiron And Human Agenda; Psychedelics Policy Tailwinds; Spac/go-public Rationale, Max Martin - Peds In Sports; Fda-approved Substances Under Medical Supervision; Irb-approved Athletic Clinical Trial In Abu Dhabi; Peptides Market Sizing; Consumer Longevity Brand (supplements/hormone Therapy/compounded Glp-1s); Spac/go-public Strategy, David Maris - Updates Since Prior Period: Glp-1 Timeline And Regulatory/legal Developments; Margins And Deal Economics; Compounded Semaglutide Pill Strategy; Medvi Scandal Implications; Peptides Outlook Into July FDA Meeting; Hims Governance/voting And Insider Selling; Short Interest; Valuation And Near-term Signals, Jonah Lupton - Peptides Thesis For Hims; FDA Advisory Meeting Implications; Gray/legitimacy Concerns; Comparative “branded Vs Compounded” Future; Partnership Landscape (lilly Vs Novo); Long-term Valuation Model; Personal Stack (peptides/glps/trt) As Illustrative Of Thesis
Recent Topics
Telehealth, Pharma, Compounding, Glp 1, Peptides, Mental Health, Healthcare, Investing, Clinical, Pharmaceuticals
Get your clients booked on top podcasts
Try us risk free with a FREE 3 days trial.
Join hundreds of PR teams using Podseeker to pitch and land bookings
